Literature DB >> 30099505

Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Joseph A Lewnard1,2, Christine Tedijanto2, Benjamin J Cowling3, Marc Lipsitch2.   

Abstract

Test-negative designs are commonplace in assessments of influenza vaccination effectiveness, estimating this value from the exposure odds ratio of vaccination among individuals treated for acute respiratory illness who test positive for influenza virus infection. This approach is widely believed to recover the vaccine direct effect by correcting for differential health-care-seeking behavior among vaccinated and unvaccinated persons. However, the relationship of the measured odds ratio to true vaccine effectiveness is poorly understood. We derived the odds ratio under circumstances of real-world test-negative studies. The odds ratio recovers the vaccine direct effect when 2 conditions are met: 1) Individuals' vaccination decisions are uncorrelated with exposure or susceptibility to the test-positive or test-negative conditions, and 2) vaccination confers "all-or-nothing" protection (whereby certain individuals have no protection while others are perfectly protected). Biased effect-size estimates arise if either condition is unmet. Such bias might suggest misleading associations of vaccine effectiveness with time since vaccination or the force of infection of influenza. The test-negative design could also fail to correct for differential health-care-seeking behavior among vaccinated and unvaccinated persons without stringent criteria for enrollment and testing. Our findings demonstrate a need to reassess how data from test-negative studies can inform policy decisions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30099505      PMCID: PMC6269249          DOI: 10.1093/aje/kwy163

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  61 in total

1.  The Advisory Committee on Immunization Practices' controversial recommendation against the use of live attenuated influenza vaccine is based on a biased study design that ignores secondary protection.

Authors:  Parker A Small; Brendan J Cronin
Journal:  Vaccine       Date:  2017-01-22       Impact factor: 3.641

2.  On measures and models for the effectiveness of vaccines and vaccination programmes.

Authors:  S Greenland; R R Frerichs
Journal:  Int J Epidemiol       Date:  1988-06       Impact factor: 7.196

3.  Waxing Understanding of Waning Immunity.

Authors:  Benjamin A Lopman; Virginia E Pitzer
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

4.  The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak.

Authors:  M Haber; W A Orenstein; M E Halloran; I M Longini
Journal:  Am J Epidemiol       Date:  1995-05-15       Impact factor: 4.897

5.  Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981.

Authors:  A S Monto; J S Koopman; I M Longini
Journal:  Am J Epidemiol       Date:  1985-06       Impact factor: 4.897

6.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

7.  Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Authors:  Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest
Journal:  Pediatr Infect Dis J       Date:  2006-10       Impact factor: 2.129

8.  The test-negative design for estimating influenza vaccine effectiveness.

Authors:  Michael L Jackson; Jennifer C Nelson
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

9.  Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study.

Authors:  Andrew S Azman; Lucy A Parker; John Rumunu; Fisseha Tadesse; Francesco Grandesso; Lul L Deng; Richard Laku Lino; Bior K Bior; Michael Lasuba; Anne-Laure Page; Lameck Ontweka; Augusto E Llosa; Sandra Cohuet; Lorenzo Pezzoli; Dossou Vincent Sodjinou; Abdinasir Abubakar; Amanda K Debes; Allan M Mpairwe; Joseph F Wamala; Christine Jamet; Justin Lessler; David A Sack; Marie-Laure Quilici; Iza Ciglenecki; Francisco J Luquero
Journal:  Lancet Glob Health       Date:  2016-11       Impact factor: 26.763

Review 10.  Vaccines for preventing influenza in the elderly.

Authors:  Vittorio Demicheli; Tom Jefferson; Carlo Di Pietrantonj; Eliana Ferroni; Sarah Thorning; Roger E Thomas; Alessandro Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01
View more
  35 in total

1.  THE AUTHORS REPLY.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2019-04-01       Impact factor: 4.897

2.  RE: "MEASUREMENT OF VACCINE DIRECT EFFECTS UNDER THE TEST-NEGATIVE DESIGN".

Authors:  Natalie E Dean
Journal:  Am J Epidemiol       Date:  2019-04-01       Impact factor: 4.897

3.  Challenges in estimating influenza vaccine effectiveness.

Authors:  Kylie E C Ainslie; Michael Haber; Walt A Orenstein
Journal:  Expert Rev Vaccines       Date:  2019-05-31       Impact factor: 5.217

4.  Uses of pathogen detection data to estimate vaccine direct effects in case-control studies.

Authors:  Joseph A Lewnard
Journal:  J R Soc Interface       Date:  2020-08-12       Impact factor: 4.118

5.  Temporal Confounding in the Test-Negative Design.

Authors:  Natalie E Dean; M Elizabeth Halloran; Ira M Longini
Journal:  Am J Epidemiol       Date:  2020-11-02       Impact factor: 4.897

6.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

7.  Waning of Measured Influenza Vaccine Effectiveness Over Time: The Potential Contribution of Leaky Vaccine Effect.

Authors:  Jerome I Tokars; Manish M Patel; Ivo M Foppa; Carrie Reed; Alicia M Fry; Jill M Ferdinands
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

8.  Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.

Authors:  Carlos G Grijalva; Leora R Feldstein; H Keipp Talbot; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Jonathan D Casey; Heidi L Erickson; Matthew C Exline; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Natasha Halasa; Akram Khan; Christopher J Lindsell; Samuel K Nwosu; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay S Steingrub; William B Stubblefield; Mark W Tenforde; Manish M Patel; Wesley H Self
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 9.079

9.  An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial.

Authors:  Li Zhang; Mingwei Wei; Pengfei Jin; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2021-02-02       Impact factor: 3.452

10.  Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.

Authors:  Minal K Patel; Isabel Bergeri; Joseph S Bresee; Benjamin J Cowling; Natasha S Crowcroft; Kamal Fahmy; Siddhivinayak Hirve; Gagandeep Kang; Mark A Katz; Claudio F Lanata; Maïna L'Azou Jackson; Sudhir Joshi; Marc Lipsitch; Jason M Mwenda; Francisco Nogareda; Walter A Orenstein; Justin R Ortiz; Richard Pebody; Stephanie J Schrag; Peter G Smith; Padmini Srikantiah; Lorenzo Subissi; Marta Valenciano; David W Vaughn; Jennifer R Verani; Annelies Wilder-Smith; Daniel R Feikin
Journal:  Vaccine       Date:  2021-06-01       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.